Invention Grant
- Patent Title: PUMA, a pro-apoptotic gene, as a novel molecular biomarker for TNFα-induced human islet damage
-
Application No.: US13163326Application Date: 2011-06-17
-
Publication No.: US09758826B2Publication Date: 2017-09-12
- Inventor: Yoko Mullen , Masato Mitsuhashi , Keiko Omori
- Applicant: Yoko Mullen , Masato Mitsuhashi , Keiko Omori
- Applicant Address: US CA Duarte US CA Irvine JP Tokyo
- Assignee: City of Hope,Hitachi Chemical Research Center, Inc.,Hitachi Chemical Co., Ltd.
- Current Assignee: City of Hope,Hitachi Chemical Research Center, Inc.,Hitachi Chemical Co., Ltd.
- Current Assignee Address: US CA Duarte US CA Irvine JP Tokyo
- Agency: Perkins Coie LLP
- Agent Courtney Prochnow
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/50

Abstract:
p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-α stimulation in a time- and dose-dependent manner and β cell apoptosis is induced through a mitochondrial pathway. TNF-α significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such β cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.
Public/Granted literature
- US20110318751A1 PUMA, A PRO-APOPTOTIC GENE, AS A NOVEL MOLECULAR BIOMARKER FOR TNFalpha-INDUCED HUMAN ISLET DAMAGE Public/Granted day:2011-12-29
Information query